


wherein the double bond is in the trans configuration and R<sub>1</sub> is a radical of formula IIa,



R<sub>2</sub>, R<sub>3</sub>, R<sub>5</sub>, R<sub>7</sub> and R<sub>8</sub> are each hydrogen,  
R<sub>4</sub> is methyl, and  
R<sub>6</sub> is a radical of formula IIIa



where R<sub>11</sub> is n-butyl, tertiary butyl or phenyl or a chemotherapeutically acceptable acid addition salt thereof.--

#### REMARKS

Claims 3 to 5, 9 to 13, and 15 to 23 have been presented for examination and claims 9 to 13 and new claim 24 are now in the Application. No additional fee is required.

Claims 9 to 13 and 23, and presumably new claim 24 are rejected under 35 USC 103 over the Hamberger et al European patent Application No. 896 and the Hamberger et al USP No. 4,680,291, which corresponds to the European patent application (both of record). The Examiner indicates that the Hamberger references set forth a class of compounds which would suggest the compounds of the instant Application and have the same utility. The Examiner argues that one of